B Cell News and Research

RSS

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Inovio Biomedical Corporation (NYSE AMEX: INO) (“Inovio”) today reported financial results for the three and six months ended June 30, 2009. Total revenue of $2.5 million and $2.9 million for the three and six months ended June 30, 2009, compared to $663,000 and $1.3 million for the three and six months ended June 30, 2008, respectively.

20 Aug 2009

Poll reveals that thin majority of Americans continue to support health care reforms

A slim majority of Americans continues to favor moving forward on health care reform now despite an intensifying ad war and a political climate of contentious town hall meetings that coincide with rising concerns about the reform effort, according to the August Kaiser Health Tracking Poll.

20 Aug 2009

Study finds long-term exposure to progesterone may lead to growth of tumors

Scientists at Michigan State University have found exposure to the hormone progesterone activates genes that trigger inflammation in the mammary gland.

20 Aug 2009

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.

20 Aug 2009

Scientists develop new technique to target brain cancer cells

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

20 Aug 2009

Steroid hormones found to affect gene activity

Intermittent signaling by steroid hormones can affect the way genes are expressed in rodents, according to research by scientists at the University of Bristol and the National Cancer Institute (NCI), USA. This work has major implications for understanding how steroids work and opens novel avenues for new therapies.

19 Aug 2009

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

19 Aug 2009

New tool for scientists - light used to manipulate cell movement

One of the biggest challenges in scientists' quest to develop new and better treatments for cancer is gaining a better understanding of how and why cancer spreads. Recent breakthroughs have uncovered how different cellular proteins are turned 'on' or 'off' at the molecular level, but much remains to be understood about how protein signaling influences cell behavior.

19 Aug 2009

Researchers find connection between eye disease and arginase

Elevated levels of the enzyme arginase contribute to vascular eye damage and Medical College of Georgia researchers say therapies to normalize its levels could halt progression of potentially blinding diseases such as diabetic retinopathy.

19 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

New "micropatterning" method useful in gene expression studies

Like oil and water, two water-based liquids can mingle without mixing in a new University of Michigan technology developed for biological experiments.

19 Aug 2009

Light-activated delivery system enhances anti-tumour drug potency

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

19 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

Novavax reports positive preclinical results for H1N1 influenza VLP vaccine

Novavax, Inc. (Nasdaq: NVAX) announced positive preclinical results with Novavax's 2009 novel H1N1 influenza virus-like particle (VLP) vaccine. The study, conducted by scientists from Novavax and the Centers for Disease Control and Prevention (CDC) based in Atlanta, GA, under a collaborative agreement, represents the first efficacy report of a 2009 novel H1N1 vaccine in ferrets. The ferret model is widely accepted to be the most appropriate animal model for evaluating influenza disease and vaccines. Novavax scientists designed the vaccine using recombinant virus like particles (VLP) technology against an H1N1 virus strain (A/California/04/2009) isolated in the beginning of the 2009 H1N1 outbreak.

19 Aug 2009

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

Research study highlights the biological importance of Vitamin D in humans and other primates

A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

Discovery of key factor that stimulates brain cancer cells to spread

Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). In a move toward therapy, the researchers showed that a small designer protein can block this activity and reduce the spreading of GBM cells grown in the laboratory.

19 Aug 2009

B Cell News and Research

Inovio Biomedical records $2.9 million revenues in the six months ended June 30, 2009

Poll reveals that thin majority of Americans continue to support health care reforms

Study finds long-term exposure to progesterone may lead to growth of tumors

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

Scientists develop new technique to target brain cancer cells

Steroid hormones found to affect gene activity

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

New tool for scientists - light used to manipulate cell movement

Researchers find connection between eye disease and arginase

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

CEL-SCI expands work on current H1N1 virus vaccine

New "micropatterning" method useful in gene expression studies

Light-activated delivery system enhances anti-tumour drug potency

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

Novavax reports positive preclinical results for H1N1 influenza VLP vaccine

Bioheart's executive management team strengthened by the inclusion of board members

Research study highlights the biological importance of Vitamin D in humans and other primates

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

New production technology to develop vaccine for norovirus

Discovery of key factor that stimulates brain cancer cells to spread

Using single B cell screening to boost antibody discovery eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News